Triglycerides dropped by 31 percent
The medication requires once-weekly subcutaneous administration and delivers consistent appetite control alongside blood sugar regulation
Then taper the supplement and monitor whether the effects persist through dietary maintenance alone
Similar findings were seen with once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) [27], demonstrating the utility of GLP-1RAs for obesity management
2022 Grade B recommendation), (2) the proposed mechanism overlap between what GLP-1 medications appear to suppress and what energy-based devices stimulate, and (3) the Catalfamo 2025 case series (PMID 40806889) showing in-clinic bipolar RF is effective for the skin laxity component of Ozempic face, which suggests the mechanism is RF-responsive even if the at-home device delivers less energy than a clinical equivalent
Supply issues and spotty insurance coverage have driven some patients to seek out compounded versions of the drug, which tend to be less expensive
